JP2020002172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020002172A5 JP2020002172A5 JP2019167098A JP2019167098A JP2020002172A5 JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5 JP 2019167098 A JP2019167098 A JP 2019167098A JP 2019167098 A JP2019167098 A JP 2019167098A JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- monoclonal antibody
- seq
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232343P | 2015-09-24 | 2015-09-24 | |
| US62/232,343 | 2015-09-24 | ||
| US201662375825P | 2016-08-16 | 2016-08-16 | |
| US62/375,825 | 2016-08-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Division JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020002172A JP2020002172A (ja) | 2020-01-09 |
| JP2020002172A5 true JP2020002172A5 (enExample) | 2020-09-10 |
Family
ID=57121460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
| JP2019167098A Pending JP2020002172A (ja) | 2015-09-24 | 2019-09-13 | （持続性）外傷後頭痛の予防、治療および低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170088612A1 (enExample) |
| EP (1) | EP3353202B1 (enExample) |
| JP (2) | JP2018532728A (enExample) |
| KR (2) | KR20200035163A (enExample) |
| CN (1) | CN108473560A (enExample) |
| AU (2) | AU2016325738A1 (enExample) |
| CA (1) | CA2999809A1 (enExample) |
| EA (1) | EA201890578A1 (enExample) |
| ES (1) | ES2846878T3 (enExample) |
| HK (1) | HK1258385A1 (enExample) |
| IL (1) | IL258008A (enExample) |
| MX (1) | MX2018003713A (enExample) |
| WO (1) | WO2017051385A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66303B1 (sr) | 2011-05-20 | 2025-01-31 | H Lundbeck As | Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene |
| SG10201604040PA (en) | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| AU2017331593B2 (en) | 2016-09-23 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| US12398209B2 (en) * | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| PE20211707A1 (es) | 2019-01-08 | 2021-09-01 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp |
| CA3133912A1 (en) * | 2019-04-18 | 2020-10-22 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| US12178862B2 (en) | 2020-06-03 | 2024-12-31 | Miotox, Llc | Zonal and targeted methods and uses for treating a migraine disorder |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704770D0 (sv) * | 1997-12-19 | 1997-12-19 | Astra Ab | New use |
| ES2433251T5 (es) * | 2005-11-14 | 2020-03-13 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos |
| SG10201604040PA (en) * | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
| BR112014016939A2 (pt) * | 2012-01-10 | 2019-09-24 | Noxxon Pharma Ag | ácidos nucleicos que se ligam especificamente a cgrp |
| US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
-
2016
- 2016-09-23 EA EA201890578A patent/EA201890578A1/ru unknown
- 2016-09-23 MX MX2018003713A patent/MX2018003713A/es unknown
- 2016-09-23 KR KR1020207008057A patent/KR20200035163A/ko not_active Withdrawn
- 2016-09-23 AU AU2016325738A patent/AU2016325738A1/en not_active Abandoned
- 2016-09-23 CA CA2999809A patent/CA2999809A1/en not_active Abandoned
- 2016-09-23 HK HK19100783.0A patent/HK1258385A1/zh unknown
- 2016-09-23 ES ES16778888T patent/ES2846878T3/es active Active
- 2016-09-23 US US15/274,331 patent/US20170088612A1/en not_active Abandoned
- 2016-09-23 WO PCT/IB2016/055720 patent/WO2017051385A1/en not_active Ceased
- 2016-09-23 CN CN201680068514.8A patent/CN108473560A/zh active Pending
- 2016-09-23 JP JP2018515658A patent/JP2018532728A/ja active Pending
- 2016-09-23 KR KR1020187011355A patent/KR20180058777A/ko not_active Ceased
- 2016-09-23 EP EP16778888.4A patent/EP3353202B1/en active Active
-
2018
- 2018-03-11 IL IL258008A patent/IL258008A/en unknown
-
2019
- 2019-06-11 US US16/437,776 patent/US20200148761A1/en not_active Abandoned
- 2019-09-13 JP JP2019167098A patent/JP2020002172A/ja active Pending
- 2019-11-06 AU AU2019261726A patent/AU2019261726A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,737 patent/US20220048986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530683A5 (enExample) | ||
| JP2008540447A5 (enExample) | ||
| JP2020503260A5 (enExample) | ||
| EP3201231B1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
| JP2014114288A5 (enExample) | ||
| JP2017510579A5 (enExample) | ||
| TW201024315A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide | |
| KR20120100914A (ko) | 에프라투주맙을 이용한 자가면역 및 염증 질환의 치료 | |
| JP2023524149A5 (enExample) | ||
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2020527152A5 (enExample) | ||
| JP2018529635A5 (enExample) | ||
| JP2022531408A5 (enExample) | ||
| RU2013157177A (ru) | Способы лечения системной красной волчанки, склеродермии и миозита | |
| JP2020515577A5 (enExample) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2021502065A5 (enExample) | ||
| US20220213203A1 (en) | Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies | |
| JP2025515092A5 (enExample) | ||
| JP2022500382A5 (enExample) | ||
| US20250263472A1 (en) | Compositions and methods for treating and suppressing allergic responses | |
| WO2023009434A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| Rose et al. | Monoclonal antibody treatments for multiple sclerosis | |
| TW202508630A (zh) | 治療表現ｃｄ２０之ｂ細胞癌症之方法 |